Simposio Internazionale
GISEA/OEG 2017
L’importanza dei registri biologici nazionali e le novità in ambito scientifico
giovedì 2 marzo 2017 - venerdì, 3 marzo 2017
Aula Magna
Facoltà di Giurisprudenza
Università degli Studi di Ferrara
corso Ercole I d’Este, 37
44121 Ferrara
SCIENTIFIC ORGANIZERS
Giovanni LAPADULA /
Gianfranco FERRACCIOLISCIENTIFIC COMMITTEE
Fabiola ATZENI Roberto CAPORALI Ennio Giulio FAVALLI Marcello GOVONI Elisa GREMESE Florenzo IANNONE Fausto SALAFFI Marco SEBASTIANIFACULTY
Federico BISCETTI Paolo BONARETTI Serena BUGATTI Luca CANTARINI Francesco Paolo CANTATORE Antonio CARLETTO Marina CAROTTI Lorenzo CAVAGNA Stefania CERRI Luca CIMINO Fabrizio CONTI Andrea DORIA Oscar Massimiliano EPISCaterina FERRELI Clodoveo FERRI Rosario FOTI Enrico FUSARO Rosario GAGLIARDI Mauro GALEAZZI James GALLOWAY Juan GOMEZ-REINO Roberto GORLA Walter GRASSI Clive KELLY Andreina MANFREDI Anna Maria MARATA Francesco Saverio MENNINI Carlomaurizio MONTECUCCO Ignazio Benedetto OLIVIERI Giuseppe PASSIU Raffaele PELLERITO Maria Beatrice PRINCIPI Leonardo PUNZI Roberta RAMONDA Maurizio ROSSINI Carlo SALVARANI Piercarlo SARZI PUTTINI Luigi SINIGAGLIA Anja STRANGFELD Giovanni TRIOLO Francesco TROTTA Giovedì 2 Marzo 2017 Sessione Corsi Monotematici9:00 - 10:30
La Medicina Comunicazionale. Imaging del Paziente Complesso 10:30 - 11:00
Golimumab persistence in therapy in real life: new evidences from Italian registries11:00 - 11:30
Efficacia di abatacept nella pratica clinica 11:30 - 11:40
AperturaSESSION I Comorbidities in Rheumatoid Arthritis: Skeletal Health 11:40 - 12:00
Rheumatoid arthritis: systemic osteoporosis and fragility fractures 12:00 - 12:20
Pathophysiology of subchondral bone erosions in rheumatoid arthritis12:20 - 12:40
Therapeutic options to preserve bone health in rheumatoid arthritis12:40 - 12:50 Discussion
12:50 - 13:20 Lettura
Nuove Terapie: Jakinibs 13:20 - 14:45 Lunch
SESSION II Infections 14:15 - 14:35
TB infections in patients with RA treated with biological agents: results from the British Register 14:35 - 14:55
Outcome of serious infections in RA patients: results from the German Biologics Register 14:55 - 15:15
Non-specific infections in patients with RA and SpA treated with biological agents15:15 - 15:30 Discussion
15:30 - 16:00 Sponsored Lecture - SANOFI
Quando l’anti-TNF in prima linea fallisce, quali sono le possibili scelte da intraprendere nel paziente affetto da AR (Artrite reumatoide)? 16:00 - 16:30 Sponsored Lecture - ABBVIE
Occhio alle spondiloartropatie SESSION III Cardiovascular Risks 16:30 - 16:50
Corticosteroids and biotechnologic drugs in disease control and CV risk: which side hangs the balance? 16:50 - 17:10
Thromboembolic risk and stroke in in ammatory arthritides 17:10 - 17:25 Discussion
17:25 - 17:55 Sponsored Lecture - CELGENE
La gestione del paziente con artrite psoriasica in assenza di fattori di prognosi severa SESSION IVImpact on the Neurologic System 17:55 - 18:15
Peripheral neuropathy in rheumatoid arthritis: a neglected comorbidity18:15 - 18:35
Central nervous system and rheumatoid arthritis: not only atloepistrophic involvement 18:35 - 18:55
Drugs and neurologic involvement in rheumatoid arthritis: myth or reality? 18:45 - 19:10 Discussion
Venerdì 3 Marzo 2017 9:00 - 9:30 Sponsored Lecture - PFIZER
An innovative management of unmet needs in RA (rheumatoid arthritis) patients to achieve a Comprehensive Disease Control 9:30 - 10:00 Sponsored Lecture - ROCHE
IL-6 inhibition in RA: tocilizumab from RCT to real world data SESSION V Lung Diseases 10:00 - 10:20
The need for an early diagnosis of Rheumatoid Arthritis related Interstitial Lung Disease 10:20 - 10:40
Clinical assessment of Rheumatoid Arthritis related Interstitial Lung Disease10:40 - 11:00
Conventional and biological DMARDs and Rheumatoid Arthritis related Interstitial Lung Disease: the problem or the solution? 11:00 - 11:15 Discussion
11:15 - 11:45
Presentazione Progetto Patient Profiling TAVOLA ROTONDA
Which future for public health care sustainability? Regional scenarios, clinical needs and working hypothesis 11:45 - 12:05
National health care system and regional scenarios 12:05 - 12:25
Clinical needs and expectancies 12:25 - 12:45
Are there suitable working hypothesis solutions? 12:45 - 13:15 Sponsored Lecture - NOVARTIS
Secukinumab: tra la real life e i dati registrativi 13:15 - 13:45 Sponsored Lecture - BIOGEN
Sostenibilità delle innovazioni farmacologiche: i biosimilari 13:45 - 14:30 Lunch
SESSION VI Skin: a “Window of Opportunity” 14:30 - 14:50
Il Progetto IDEA: final report 14:50 - 15:20 Lettura
PsA e obesità 15:20 - 15:40
Skin and Psoriatic Arthritis15:40 - 16:00
Skin and In ammatory Bowel Diseases 16:00 - 16:20
Skin and Rare Diseases 16:20 - 16:35 Discussion
